Christopher Kimberlin
About Christopher Kimberlin
Christopher Kimberlin is a Senior Scientist II at Asher Biotherapeutics, specializing in the design and characterization of protein constructs. With a PhD in Structural Biology, he has extensive experience in biotherapeutic design and has contributed to research in viral pathogenesis and CAR-T cell therapies.
Current Role at Asher Biotherapeutics
Christopher Kimberlin serves as a Senior Scientist II at Asher Biotherapeutics, a position he has held since 2020. He works in South San Francisco, focusing on the design, expression, purification, and characterization of protein constructs, including Fabs and secreted/glycoproteins. His role involves adapting to new challenges and collaborating effectively within team environments.
Previous Experience at Pfizer
Before joining Asher Biotherapeutics, Kimberlin worked at Pfizer as a Senior Scientist in Biotherapeutic Design and Discovery from 2016 to 2019. His tenure at Pfizer lasted three years and took place in South San Francisco, where he contributed to various projects in biotherapeutics.
Educational Background
Christopher Kimberlin earned his Bachelor of Science degree in Biological Sciences from the University of California, Santa Barbara, from 1999 to 2003. He furthered his education at The Scripps Research Institute, where he completed his Ph.D. in Structural Biology from 2004 to 2010. His academic training laid the foundation for his expertise in protein characterization and structural biology.
Research Contributions and Expertise
Kimberlin has a broad interest in research with direct applications to human disease, particularly in viral pathogenesis. He possesses expertise in X-ray crystallography and small angle X-ray scattering, focusing on challenging protein targets such as protein-protein, protein-RNA, and protein-lipid complexes. His contributions include research on engineered cell surface tag-targeted IL-2 and IL-21 to enhance CAR-T anti-tumor activity.
Conference Participation
Christopher Kimberlin has actively participated in significant scientific conferences, including the American Association of Cancer Research (AACR) conference in April 2022 and the American Society of Hematology (ASH) conference in December 2022. His involvement in these events underscores his commitment to staying engaged with the latest developments in his field.